ELDN · Eledon Pharmaceuticals Inc. Common Stock
View on chartInsiders & Stakes
| BVF PARTNERS L P/IL 10% Owner | ▲ Buy | Open Market | 220,460 Shares held | 5/9/2024 | View profile |
| David-Alexandre C. Gros Chief Executive Officer | ▼ Sell | Tax Withholding | 168,663 Shares held | 7/31/2026 | View profile |
| Steven Perrin President | ▼ Sell | Tax Withholding | 81,215 Shares held | 7/31/2026 | View profile |
| Keith Katkin Director | ▲ Buy | Option Exercise | 8,575 Shares held | 1/10/2026 | View profile |
| John S. McBride | ▲ Buy | Option Exercise | 3,430 Shares held | 1/10/2026 | View profile |
| Jan Hillson | ▲ Buy | Option Exercise | 3,430 Shares held | 1/10/2026 | View profile |
| Allan Kirk | ▲ Buy | Option Exercise | 3,430 Shares held | 1/10/2026 | View profile |
| June Lee | ▲ Buy | Option Exercise | 3,430 Shares held | 1/10/2026 | View profile |
| James A. Robinson Jr. Director | ▲ Buy | Option Exercise | 3,430 Shares held | 1/10/2026 | View profile |
Transaction History
| Steven Perrin | ▲ Buy | Grant | 152,353 | $0 | 7/31/2026 |
| Steven Perrin | ▼ Sell | Tax Withholding | 72,138 | $244K | 7/31/2026 |
| David-Alexandre C. Gros | ▲ Buy | Grant | 354,454 | $0 | 7/31/2026 |
| David-Alexandre C. Gros | ▼ Sell | Tax Withholding | 194,791 | $658K | 7/31/2026 |
| June Lee | ▲ Buy | Option Exercise | 3,430 | $0 | 1/10/2026 |
| Jan Hillson | ▲ Buy | Option Exercise | 3,430 | $0 | 1/10/2026 |
| James A. Robinson Jr. | ▲ Buy | Option Exercise | 3,430 | $0 | 1/10/2026 |
| Allan Kirk | ▲ Buy | Option Exercise | 3,430 | $0 | 1/10/2026 |
| Keith Katkin | ▲ Buy | Option Exercise | 8,575 | $0 | 1/10/2026 |
| John S. McBride | ▲ Buy | Option Exercise | 3,430 | $0 | 1/10/2026 |
| BVF PARTNERS L P/IL | ▲ Buy | Open Market | 1,031,385 | — | 5/9/2024 |
| BVF PARTNERS L P/IL | ▲ Buy | Open Market | 821,121 | — | 5/9/2024 |
| BVF PARTNERS L P/IL | ▲ Buy | Open Market | 75,431 | — | 5/9/2024 |
| BVF PARTNERS L P/IL | ▲ Buy | Open Market | 1,055,445 | — | 5/5/2023 |
| BVF PARTNERS L P/IL | ▲ Buy | Open Market | 837,146 | — | 5/5/2023 |
| BVF PARTNERS L P/IL | ▲ Buy | Open Market | 86,341 | — | 5/5/2023 |
| Steven Perrin | ▲ Buy | Open Market | 1,000 | $3K | 11/23/2022 |
| David-Alexandre C. Gros | ▲ Buy | Open Market | 2,000 | $9K | 12/20/2021 |
| David-Alexandre C. Gros | ▲ Buy | Open Market | 4,000 | $25K | 8/17/2021 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
ELDN Presents Phase 2 Data, Gets FDA Fast Track for Tegoprubart
Eledon presented updated long‑term results from its Phase 2 BESTOW extension study at the International Congress of The Transplantation Society. The data support the continued development of tegoprubart for kidney transplant patients. The FDA also granted Fast Track designation for tegoprubart, and the company plans to start a Phase 3 LEGACY study in the fourth quarter of 2026. These milestones highlight progress in the company’s clinical program.
ELDN Presents Phase 2 Data, Gets FDA Fast Track for Tegoprubart. Eledon presented updated long‑term results from its Phase 2 BESTOW extension study at the International Congress of The Transplantation Society. The data support the continued development of tegoprubart for kidney transplant patients. The FDA also granted Fast Track designation for tegoprubart, and the company plans to start a Phase 3 LEGACY study in the fourth quarter of 2026. These milestones highlight progress in the company’s clinical program.